In 2024 consensus-based guidance was formulated by representatives from the American Society of Anesthesiologists (ASA), the American Gastrointestinal Association (AGA), the American Society for Metabolic and Bariatric Surgery (ASMBS), the International Society of Perioperative Care of Patients with Obesity (ISPCOP), and the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) [19], according to which, use of GLP-1RAs and the management in the perioperative period should be based on shared decision-making of the patient, the anaesthetist, the prescribing care team, and the surgeon [19, 20]
Novel Skeletal Effects of Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
Bansal S, Canziani MEF, Birne R, et al
Anticarcinogenic action of quercetin by downregulation of phosphatidylinositol 3-kinase (PI3K) and protein kinase C (PKC) via induction of p53 in hepatocellular carcinoma (HepG2) cell line
While this effect is often desired, its essential to be aware that its temporary and will gradually fade over time